Immune Response to Influenza Vaccine in ESRD Patients

Mahidol University

Status: Completed

Conditions: Immunology; Nephrology

Treatments: Biological: Influenza vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT04122222

07-59-14

Details and patient eligibility

About

On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We aimed to study the immune responses to influenza vaccine in dialysis patients treated by HDF vs. HD.

Enrollment: 60 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• ESRD patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (HDF) or conventional high flux hemodialysis (HD), with a session dialyzer urea clearance (Kt/V urea) of 1.2 and greater, with a convection volume target of 20 L/session for the HDF group

Exclusion criteria

• Had received any vaccination within the previous four weeks, or influenza vaccination within six months
• Patient who reported upper respiratory tract symptoms within three days prior to the study vaccination
• A history of allergy to influenza vaccine or egg
• Thrombocytopenia
• In receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Hemodialysis

Active Comparator group

Description:

ESRD patients treated by hemodialysis

Treatment:

Biological: Influenza vaccine

Hemodiafiltration

Active Comparator group

Description:

ESRD patients treated by on-line hemodiafiltration

Treatment:

Biological: Influenza vaccine